Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination and survival of ovarian carcinoma xenograft models
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination and survival of ovarian carcinoma xenograft models
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CANCER
Volume 107, Issue 2, Pages 360-369
Publisher
Springer Nature
Online
2012-06-20
DOI
10.1038/bjc.2012.261
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Evaluation of combined bevacizumab and intraperitoneal carboplatin or paclitaxel therapy in a mouse model of ovarian cancer
- (2011) Dhaval K. Shah et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian cancer
- (2011) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- Ovarian Cancer Treatments on the Horizon
- (2011) C. Schmidt JNCI-Journal of the National Cancer Institute
- Antiangiogenic therapy: impact on invasion, disease progression and metastasis
- (2011) John M. L. Ebos et al. Nature Reviews Clinical Oncology
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the welfare and use of animals in cancer research
- (2010) P Workman et al. BRITISH JOURNAL OF CANCER
- Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy
- (2010) A. Bagri et al. CLINICAL CANCER RESEARCH
- Trials With Impact on Clinical Management
- (2010) Michael A. Bookman INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?
- (2010) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Disease Course Patterns After Discontinuation of Bevacizumab: Pooled Analysis of Randomized Phase III Trials
- (2010) David Miles et al. JOURNAL OF CLINICAL ONCOLOGY
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology
- (2009) L. M. Ellis et al. CLINICAL CANCER RESEARCH
- Phase II Study of Carboplatin, Paclitaxel, and Bevacizumab With Maintenance Bevacizumab As First-Line Chemotherapy for Advanced Müllerian Tumors
- (2009) Richard T. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Drug resistance associated with antiangiogenesis therapy
- (2009) Hans Petter Eikesdal et al. SEMINARS IN CANCER BIOLOGY
- Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
- (2008) S. Mabuchi et al. CLINICAL CANCER RESEARCH
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis
- (2008) Ifat Sher et al. INTERNATIONAL JOURNAL OF CANCER
- Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
- (2008) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now